Orphazyme A/S [NASDAQ: ORPH] stock went on an upward path that rose over 24.62% on Wednesday, amounting to a one-week price decrease of less than -54.10%. The company report on June 23, 2021 that Major shareholder announcement.
Orphazyme A/SCompany announcement No. 18/2021Company Registration No. 32266355.
The one-year Orphazyme A/S stock forecast points to a potential upside of 29.14. The average equity rating for ORPH stock is currently 3.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $260.04 million, with 34.95 million shares outstanding and 24.59 million shares in the current float. Compared to the average trading volume of 7.39M shares, ORPH stock reached a trading volume of 131437979 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Orphazyme A/S [ORPH]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ORPH shares is $10.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ORPH stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Guggenheim have made an estimate for Orphazyme A/S shares, keeping their opinion on the stock as Sell, with their previous recommendation back on June 21, 2021. While these analysts kept the previous recommendation, BofA Securities raised their target price from $13 to $5. The new note on the price target was released on March 30, 2021, representing the official price target for Orphazyme A/S stock. Previously, the target price had yet another raise to $27, while Guggenheim analysts kept a Buy rating on ORPH stock.
The Average True Range (ATR) for Orphazyme A/S is set at 5.27
ORPH Stock Performance Analysis:
Orphazyme A/S [ORPH] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -54.10. With this latest performance, ORPH shares gained by 31.72% in over the last four-week period, additionally sinking by -34.16% over the last 6 months.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ORPH stock in for the last two-week period is set at 48.46, with the RSI for the last a single of trading hit 47.25, and the three-weeks RSI is set at 48.77 for Orphazyme A/S [ORPH]. The present Moving Average for the last 50 days of trading for this stock 7.95, while it was recorded at 8.36 for the last single week of trading.
Insight into Orphazyme A/S Fundamentals:
Return on Total Capital for ORPH is now -148.19, given the latest momentum, and Return on Invested Capital for the company is -164.77. Return on Equity for this stock declined to -188.05, with Return on Assets sitting at -126.24. When it comes to the capital structure of this company, Orphazyme A/S [ORPH] has a Total Debt to Total Equity ratio set at 11.40. Additionally, ORPH Total Debt to Total Capital is recorded at 10.23, with Total Debt to Total Assets ending up at 8.60. Long-Term Debt to Equity for the company is recorded at 5.43, with the Long-Term Debt to Total Capital now at 4.88.
Reflecting on the efficiency of the workforce at the company, Orphazyme A/S [ORPH] managed to generate an average of -$4,491,106 per employee.
Orphazyme A/S [ORPH] Insider Position Details
Positions in Orphazyme A/S stocks held by institutional investors increased at the end of June and at the time of the June reporting period, where 4 institutional holders increased their position in Orphazyme A/S [NASDAQ:ORPH] by around 138,900 shares. Additionally, 4 investors decreased positions by around 22,283 shares, while 1 investors held positions by with 128,278 shares. The mentioned changes placed institutional holdings at 289,461 shares, according to the latest SEC report filing. ORPH stock had 4 new institutional investments in for a total of 138,900 shares, while 0 institutional investors sold positions of 0 shares during the same period.